By Jacqueline Carrico, BS, MD Candidate
Given the rapid advances in CAR-T therapy, there have been major efforts to improve the specificity and safety of these therapies. Very few targets exist that are only expressed in the malignant cell population, resulting in on-target/off-tumor toxicities. Most have been minor and controllable; however, several trials have been terminated due to severe and life-threatening toxicities. There is increasing concern about this problem with dually targeted therapies, such as dual-CAR or tandem CAR.
Synthetic Notch Receptors
One approach to increasing on-tumor specificity is the development of CAR-T cells that express synthetic...